Schrodinger Inc. (SDGR)
SDGR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/0001490978-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SDGR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001490978 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $255.9M |
| Net income | -$103.3M |
| Operating income | -$166.9M |
| Net margin | -40.4% |
| Operating margin | -65.2% |
| Revenue growth | +23.3% |
| Cash | $230.5M |
| Total assets | $726.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $247.0M cash; operating cash flow -$28.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 75,077,794 (2026-10-28); 73,664,703 a year earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Portland, Oregon, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $64.5M | -$37.7M | -$47.6M | $247.0M | No debt tags | $269.2M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $58.9M | $6.0M | -$34.1M | $287.9M | No debt tags | $259.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $58.6M | -$60.0M | -$14.8M | $260.3M | No debt tags | $254.9M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $87.2M | $32.5M | -$16.1M | $230.5M | No debt tags | $255.9M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $54.3M | -$32.8M | -$61.9M | $172.1M | No debt tags | $257.0M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $54.8M | -$43.2M | -$52.2M | $219.9M | No debt tags | $237.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $59.6M | -$59.8M | $144.1M | $326.0M | No debt tags | $230.5M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $88.3M | -$40.2M | -$31.1M | $147.3M | No debt tags | $207.5M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-02-28 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 545 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.0% |
| 1 month | +14.1% |
| 3 months | +60.0% |
| Year to date | +65.2% |
| 1 year | +71.7% |
| From 52-week high | -11.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc | $15.48 | -1.59% | $2.1B |
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier